Cargando…
Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors
A new series of arylmethylene hydrazine derivatives bearing 1,3-dimethylbarbituric moiety 7a–o were designed, synthesized, and evaluated for their in vitro urease inhibitory activity. All the title compounds displayed high anti-urease activity, with IC(50) values in the range of 0.61 ± 0.06–4.56 ± 0...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134453/ https://www.ncbi.nlm.nih.gov/pubmed/34012008 http://dx.doi.org/10.1038/s41598-021-90104-x |
_version_ | 1783695178894147584 |
---|---|
author | Pedrood, Keyvan Azizian, Homa Montazer, Mohammad Nazari Mohammadi‐Khanaposhtani, Maryam Asgari, Mohammad Sadegh Asadi, Mehdi Bahadorikhalili, Saeed Rastegar, Hossein Larijani, Bagher Amanlou, Massoud Mahdavi, Mohammad |
author_facet | Pedrood, Keyvan Azizian, Homa Montazer, Mohammad Nazari Mohammadi‐Khanaposhtani, Maryam Asgari, Mohammad Sadegh Asadi, Mehdi Bahadorikhalili, Saeed Rastegar, Hossein Larijani, Bagher Amanlou, Massoud Mahdavi, Mohammad |
author_sort | Pedrood, Keyvan |
collection | PubMed |
description | A new series of arylmethylene hydrazine derivatives bearing 1,3-dimethylbarbituric moiety 7a–o were designed, synthesized, and evaluated for their in vitro urease inhibitory activity. All the title compounds displayed high anti-urease activity, with IC(50) values in the range of 0.61 ± 0.06–4.56 ± 0.18 µM as compared to the two standard inhibitors hydroxyurea (IC(50) = 100 ± 0.15 μM) and thiourea (IC(50) = 23 ± 1.7 μM). Among the synthesized compounds, compound 7h with 2-nitro benzylidene group was found to be the most potent compound. Kinetic study of this compound revealed that it is a mix-mode inhibitor against urease. Evaluation of the interaction modes of the synthesized compounds in urease active site by molecular modeling revealed that that compounds with higher urease inhibitor activity (7h, 7m, 7c, 7l, 7i, and 7o, with IC(50) of 0.61, 0.86, 1.2, 1.34, 1.33, 1.94 μM, respectively) could interact with higher number of residues, specially Arg609, Cys592 (as part of urease active site flap) and showed higher computed free energy, while compounds with lower urease activity (7f, 7n, 7g, and 7a with IC(50) of 3.56, 4.56, 3.62 and 4.43 μM, respectively) and could not provide the proper interaction with Arg609, and Cys592 as the key interacting residues along with lower free binding energy. MD investigation revealed compound 7h interacted with Arg609 and Cys592 which are of the key residues at the root part of mobile flap covering the active site. Interacting with the mentioned residue for a significant amount of time, affects the flexibility of the mobile flap covering the active site and causes inhibition of the ureolytic activity. Furthermore, in silico physico-chemical study of compounds 7a–o predicted that all these compounds are drug-likeness with considerable orally availability. |
format | Online Article Text |
id | pubmed-8134453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81344532021-05-25 Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors Pedrood, Keyvan Azizian, Homa Montazer, Mohammad Nazari Mohammadi‐Khanaposhtani, Maryam Asgari, Mohammad Sadegh Asadi, Mehdi Bahadorikhalili, Saeed Rastegar, Hossein Larijani, Bagher Amanlou, Massoud Mahdavi, Mohammad Sci Rep Article A new series of arylmethylene hydrazine derivatives bearing 1,3-dimethylbarbituric moiety 7a–o were designed, synthesized, and evaluated for their in vitro urease inhibitory activity. All the title compounds displayed high anti-urease activity, with IC(50) values in the range of 0.61 ± 0.06–4.56 ± 0.18 µM as compared to the two standard inhibitors hydroxyurea (IC(50) = 100 ± 0.15 μM) and thiourea (IC(50) = 23 ± 1.7 μM). Among the synthesized compounds, compound 7h with 2-nitro benzylidene group was found to be the most potent compound. Kinetic study of this compound revealed that it is a mix-mode inhibitor against urease. Evaluation of the interaction modes of the synthesized compounds in urease active site by molecular modeling revealed that that compounds with higher urease inhibitor activity (7h, 7m, 7c, 7l, 7i, and 7o, with IC(50) of 0.61, 0.86, 1.2, 1.34, 1.33, 1.94 μM, respectively) could interact with higher number of residues, specially Arg609, Cys592 (as part of urease active site flap) and showed higher computed free energy, while compounds with lower urease activity (7f, 7n, 7g, and 7a with IC(50) of 3.56, 4.56, 3.62 and 4.43 μM, respectively) and could not provide the proper interaction with Arg609, and Cys592 as the key interacting residues along with lower free binding energy. MD investigation revealed compound 7h interacted with Arg609 and Cys592 which are of the key residues at the root part of mobile flap covering the active site. Interacting with the mentioned residue for a significant amount of time, affects the flexibility of the mobile flap covering the active site and causes inhibition of the ureolytic activity. Furthermore, in silico physico-chemical study of compounds 7a–o predicted that all these compounds are drug-likeness with considerable orally availability. Nature Publishing Group UK 2021-05-19 /pmc/articles/PMC8134453/ /pubmed/34012008 http://dx.doi.org/10.1038/s41598-021-90104-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Pedrood, Keyvan Azizian, Homa Montazer, Mohammad Nazari Mohammadi‐Khanaposhtani, Maryam Asgari, Mohammad Sadegh Asadi, Mehdi Bahadorikhalili, Saeed Rastegar, Hossein Larijani, Bagher Amanlou, Massoud Mahdavi, Mohammad Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors |
title | Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors |
title_full | Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors |
title_fullStr | Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors |
title_full_unstemmed | Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors |
title_short | Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors |
title_sort | arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134453/ https://www.ncbi.nlm.nih.gov/pubmed/34012008 http://dx.doi.org/10.1038/s41598-021-90104-x |
work_keys_str_mv | AT pedroodkeyvan arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT azizianhoma arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT montazermohammadnazari arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT mohammadikhanaposhtanimaryam arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT asgarimohammadsadegh arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT asadimehdi arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT bahadorikhalilisaeed arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT rastegarhossein arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT larijanibagher arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT amanloumassoud arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors AT mahdavimohammad arylmethylenehydrazinederivativescontaining13dimethylbarbituricmoietyasnovelureaseinhibitors |